Alchemia establishes level 1 ADR program
Friday, 20 August, 2004
Brisbane biotech Alchemia (ASX: ACL) has taken the first step towards a NASDAQ listing, announcing it will be establishing a Level One American Depositary Receipt (ADR) program in coming months.
Managing director Dr Tracie Ramsdale said a NASDAQ listing was a natural extension of the company’s increasing focus on the United States, which was the primary market for its future products.
Earlier this month, Alchemia completed the scale-up of the manufacturing process for its synthetic heparin, which it is developing with partners Dow Chemical and American Pharmaceutical Partners.
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
Archer completes potassium sensing alpha prototype
Quantum technology company Archer Materials Limited has developed an early Biochip prototype...
Farm animals and aquaculture cryopreservation partnership announced
Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...
